Results 161 to 170 of about 9,715,620 (203)

β3‐Adrenoceptor Agonists for Neurogenic Lower Urinary Tract Dysfunction: Evidence and Clinical Rationale for First‐Line Therapy

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims To summarize current evidence on β3‐adrenoceptor agonists for managing neurogenic lower urinary tract dysfunction (NLUTD), focusing on their efficacy, safety, and clinical role in optimizing bladder storage and protecting upper tracts. Methods Evidence from randomized controlled trials, meta‐analyses, and observational studies in spinal ...
Sharon E. Fishberg, Rano Matta
wiley   +1 more source

Impact of COVID‐19 and Vaccination on Lower Urinary Tract Symptoms: Insights From a Prospective Cohort Study

Neurourology and Urodynamics, EarlyView.
ABSTRACT Aims To evaluate the prevalence, clinical course, and risk factors of lower urinary tract symptoms (LUTS) in patients hospitalized with COVID‐19, and to assess associations with comorbidities, disease severity, and vaccination status. Methods We conducted a prospective cohort study of adult patients hospitalized with confirmed COVID‐19, who ...
Julia Duarte de Souza, Jose de Bessa Jr., Natássia Cristina Carboni Truzzi, Carolina Trigo Rocha, Bruno Camargo Rocha Paim de Araujo, Julyana Kanate Mazzoni Moromizato, Thulio Bosi Vieira Brandão, Rachel Mazoni Costa, Marcelo Hisano, Zein Mohamed Sammour, Homero Bruschini, William Carlos Nahas, Cristiano Mendes Gomes   +12 more
wiley   +1 more source

“What Medical Management Should Be First Line for Bladder Storage Symptoms in NLUTD”—Pro Botox

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objectives Neurogenic lower urinary tract dysfunction (NLUTD) severely impairs patient quality of life (QoL). While oral medications are often first‐line treatments, their high failure rates and side effects limit their effectiveness. Thus, we argue for the use of intravesical botulinum toxin A (BoNT‐A) injections as a first‐line alternative ...
Vada Furlan, Alyssa Kobayashi, Zhina Sadeghi   +2 more
wiley   +1 more source

How Can We Personalize the Delivery of Onabotulinumtoxin‐A for Patients With Neurogenic Lower Urinary Tract Dysfunction?

Neurourology and Urodynamics, EarlyView.
ABSTRACT Background & Aims Neurogenic lower urinary tract dysfunction (NLUTD) can produce bothersome urinary symptoms, impact quality of life, and in some cases, lead to deterioration of upper urinary tract function. Intradetrusor injection of onabotulinumtoxin‐A (BoNT‐A) is approved for NLUTD in patients who have an inadequate response to or ...
Shirley L. Wang, William I. Jaffe, Ariana L. Smith   +2 more
wiley   +1 more source

Mirabegron and Intradetrusor Onabotulinumtoxina for Overactive Bladder in Parkinson's Disease: A Systematic Review and Meta‐Analysis

Neurourology and Urodynamics, EarlyView.
ABSTRACT Objective To synthesize the evidence on the efficacy and safety of mirabegron and intradetrusor onabotulinumtoxinA (BoNT‐A) as separate interventions for overactive bladder (OAB) in Parkinson's disease (PD). Methods A systematic review and meta‐analysis with parallel synthesis of two distinct interventions was conducted of randomized and ...
Hussain Arshad, Raiyana Nuha, Shehab Khashaba, David Gillatt, Simon J. G. Lewis   +4 more
wiley   +1 more source

Advancing Personalized Care for Neurogenic Bladder: The Case for Continent Urinary Diversion

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Neurogenic lower urinary tract dysfunction (NLUTD) with a poorly compliant bladder that is refractory to minimally invasive therapies (MIT) represents an “end‐stage” phenotype in which the principal objectives are durable upper urinary tract protection and restoration of continence with acceptable long‐term morbidity.
Francis A. Jefferson, Maude E. Carmel
wiley   +1 more source

Epidemiology and impact of catheter-related infections

, 2006
Pittet, D., Eggimann, P.
core   +1 more source

Are Age and Voided Volume Sufficient to Predict Detrusor Underactivity in Women? An External Validation Study

Neurourology and Urodynamics, EarlyView.
ABSTRACT Purpose Detrusor underactivity (DU) is a significant cause of female lower urinary tract symptoms. We aimed to externally validate a non‐invasive prediction model using age and voided volume (VV) in a tertiary center cohort. Methods This retrospective study included 450 consecutive women who underwent uroflowmetry and subsequently multichannel
Netanel Levin, Elad Yosef, Rony Vainrib, Matan Linevitz, Yanay Shaked, Amos Neheman, Michael Vainrib, Omri Schwarztuch Gildor   +7 more
wiley   +1 more source

New and Emerging Artificial Urinary Sphincters for Male Stress Urinary Incontinence: From Gold Standard to Next Generation

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction For more than four decades, the AMS‐800 has remained the clinical benchmark device for the treatment of male stress urinary incontinence (SUI). Although it remains the gold standard for male SUI, the AMS‐800 has continued to have limitations such as suboptimal post‐operative continence rates, fixed hydraulic pressure, need for ...
Erin C. Schnell, Connie N. Wang, Eric S. Rovner   +2 more
wiley   +1 more source

Determinants of Estrogen Prescriptions for Recurrent Urinary Tract Infections

Neurourology and Urodynamics, EarlyView.
ABSTRACT Introduction Vaginal estrogen is a highly effective, evidence‐based prevention method for postmenopausal women with recurrent urinary tract infections (UTIs), yet studies suggest its underutilization by non‐specialist providers. Guided by the Consolidated Framework for Implementation Research (CFIR), this study examined adoption, fidelity, and
Kelly F. Oechsel, Lei A. Qin, Minyoung Jang, Nathanael Koelper, Christine M. Chu, Shafinaz Akhter, Lily A. Arya   +6 more
wiley   +1 more source